A Phase 2b Open-label Clinical Study to Evaluate the Tolerability and Safety of an Initiation Dose of 5 mg of Vericiguat in Participants With Chronic Heart Failure With Reduced Ejection Fraction
Latest Information Update: 20 Aug 2024
At a glance
- Drugs Vericiguat (Primary)
- Indications Chronic heart failure
- Focus Adverse reactions
- Sponsors Bayer
- 16 Aug 2024 Status changed from active, no longer recruiting to completed.
- 05 Jul 2024 Planned End Date changed from 7 Jan 2025 to 31 Jul 2024.
- 05 Jul 2024 Planned primary completion date changed from 7 Jan 2025 to 31 Jul 2024.